Sarepta Therapeutics (SRPT) Return on Invested Capital (2017 - 2026)

Sarepta Therapeutics' Return on Invested Capital history runs 6 years deep, the most recent figure standing at 0.03% for Q1 2026.

• On a quarterly basis, Return on Invested Capital fell 2.0% year-over-year to 0.03% in Q1 2026; TTM through Mar 2026 was 0.03%, a 2.0% decrease from a year earlier, with the FY2017 full-year figure at 0.36%, changed N/A from the prior year.
• Return on Invested Capital grew to 0.03% in Q1 2026 per SRPT's latest filing, from 0.2% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.01% in Q4 2024 and bottomed at 0.2% in Q4 2025.
• The 3-year median for Return on Invested Capital is 0.0% (2024), against an average of 0.03%.
• Biggest YoY gain for Return on Invested Capital was 0 bps in 2025; the steepest drop was 20 bps in 2025.
• Year by year, Return on Invested Capital stood at 0.01% in 2024, then sank by 3531 bps to 0.2% in 2025, then surged by 85 bps to 0.03% in 2026.
• Per Business Quant, the three latest SRPT Return on Invested Capital figures stand at 0.03% (Q1 2026), 0.2% (Q4 2025), and 0.02% (Q3 2025).